Benoît Samson

1.1k total citations
22 papers, 336 citations indexed

About

Benoît Samson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Benoît Samson has authored 22 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Benoît Samson's work include Colorectal Cancer Treatments and Studies (17 papers), Gastric Cancer Management and Outcomes (9 papers) and Cancer Treatment and Pharmacology (9 papers). Benoît Samson is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Gastric Cancer Management and Outcomes (9 papers) and Cancer Treatment and Pharmacology (9 papers). Benoît Samson collaborates with scholars based in Canada, France and Austria. Benoît Samson's co-authors include Jean A. Maroun, Michael P. Thirlwell, Ronald L. Burkes, Scot Dowden, Normand Blais, Amil M. Shah, Lowell Anthony, George Dranitsaris, Mark Vincent and Nathalie Aucoin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Benoît Samson

22 papers receiving 324 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benoît Samson Canada 10 246 137 55 43 41 22 336
Nadine M Magoski Canada 8 215 0.9× 148 1.1× 48 0.9× 34 0.8× 37 0.9× 12 395
Pranshu Bansal United States 11 289 1.2× 218 1.6× 40 0.7× 121 2.8× 50 1.2× 21 510
Luis López‐Gómez Spain 9 278 1.1× 116 0.8× 77 1.4× 16 0.4× 44 1.1× 16 334
Anna Tomiak Canada 10 259 1.1× 184 1.3× 34 0.6× 57 1.3× 84 2.0× 17 404
Takanori Kawabata Japan 10 140 0.6× 122 0.9× 35 0.6× 18 0.4× 44 1.1× 29 273
Louise Nott Australia 11 360 1.5× 161 1.2× 87 1.6× 46 1.1× 87 2.1× 65 456
Karen Daily United States 10 138 0.6× 94 0.7× 29 0.5× 50 1.2× 56 1.4× 47 310
Babar Bashir United States 13 178 0.7× 76 0.6× 28 0.5× 95 2.2× 52 1.3× 67 403
Jun Dong China 11 128 0.5× 87 0.6× 44 0.8× 55 1.3× 61 1.5× 42 285
Dongbok Shin South Korea 8 82 0.3× 93 0.7× 41 0.7× 55 1.3× 42 1.0× 11 270

Countries citing papers authored by Benoît Samson

Since Specialization
Citations

This map shows the geographic impact of Benoît Samson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benoît Samson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benoît Samson more than expected).

Fields of papers citing papers by Benoît Samson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benoît Samson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benoît Samson. The network helps show where Benoît Samson may publish in the future.

Co-authorship network of co-authors of Benoît Samson

This figure shows the co-authorship network connecting the top 25 collaborators of Benoît Samson. A scholar is included among the top collaborators of Benoît Samson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benoît Samson. Benoît Samson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheema, Parneet, Yi‐Long Wu, Thomas John, et al.. (2021). 1165P Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial. Annals of Oncology. 32. S936–S937. 1 indexed citations
2.
Chen, Eric Xueyu, Derek J. Jonker, Hagen F. Kennecke, et al.. (2019). CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).. Journal of Clinical Oncology. 37(4_suppl). 481–481. 37 indexed citations
3.
4.
Chibaudel, Benoist, Thierry André, Benoît Samson, et al.. (2018). Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial.. Journal of Clinical Oncology. 36(4_suppl). 737–737. 2 indexed citations
5.
Boily, Gino, Édith Filion, Neil Kopek, et al.. (2015). Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non–Small-Cell Lung Cancer: CEPO Review and Recommendations. Journal of Thoracic Oncology. 10(6). 872–882. 28 indexed citations
6.
Tsvetkova, Elena, Nathalie Aucoin, James Biagi, et al.. (2015). Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. Current Oncology. 22(4). 305–315. 1 indexed citations
7.
Tremblay, Dominique, et al.. (2014). Conditions for production of interdisciplinary teamwork outcomes in oncology teams: protocol for a realist evaluation. Implementation Science. 9(1). 76–76. 11 indexed citations
8.
Chibaudel, Benoist, Christophe Tournigand, Benoît Samson, et al.. (2014). Bevacizumab-Erlotinib As Maintenance Therapy in Metastatic Colorectal Cancer. Final Results of the Gercor Dream Study. Annals of Oncology. 25. iv167–iv167. 9 indexed citations
9.
Samson, Benoît, Christophe Tournigand, Werner Scheithauer, et al.. (2013). Bevacizumab (Bev) with or without erlotinib as maintenance therapy, in patients (pts) with metastatic colorectal cancer (mCRC): Exploratory analysis according to KRAS status in the gercor DREAM phase III trial.. Journal of Clinical Oncology. 31(4_suppl). 448–448. 4 indexed citations
10.
Tournigand, Christophe, Werner Scheithauer, Benoît Samson, et al.. (2013). Induction treatment in first-line with chemotherapy + bevacizumab (bev) in metastatic colorectal cancer: Results from the gercor-DREAM phase III study.. Journal of Clinical Oncology. 31(4_suppl). 457–457. 2 indexed citations
11.
12.
Gill, Sharlene, Scott Berry, James Biagi, et al.. (2011). Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Current Oncology. 18(0). S5–S10. 21 indexed citations
13.
Aubin, F., Sharlene Gill, Ronald L. Burkes, et al.. (2011). Canadian Expert Group Consensus Recommendations: KRAS Testing in Colorectal Cancer. Current Oncology. 18(4). 180–184. 20 indexed citations
14.
Warren, Stephen L., John Nemunaitis, Joe Stephenson, et al.. (2011). Abstract 2242: A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor Dinaciclib (SCH 727965) in patients with non-small cell lung cancer (NSCLC). Cancer Research. 71(8_Supplement). 2242–2242. 1 indexed citations
15.
Samson, Benoît, Jean Latreille, Nghia T. Nguyen, et al.. (2011). SUNCAP, a phase II study with sunitinib and capecitabine in patients with metastatic colorectal cancer (MCRC) refractory to previous treatment with 5FU/irinotecan/oxaliplatin.. Journal of Clinical Oncology. 29(4_suppl). 545–545. 6 indexed citations
16.
Cripps, C., Sharlene Gill, Shahid Ahmed, et al.. (2010). Consensus Recommendations for the Use of Anti-EGFR Therapies in Metastatic Colorectal Cancer. Current Oncology. 17(6). 39–45. 7 indexed citations
17.
Tournigand, C., Benoît Samson, Werner Scheithauer, et al.. (2009). mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study. Journal of Clinical Oncology. 27(15_suppl). 4077–4077. 9 indexed citations
18.
Maroun, Jean A., Lowell Anthony, Normand Blais, et al.. (2007). Prevention and Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer: A Consensus Statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Current Oncology. 14(1). 13–20. 109 indexed citations
19.
Hirsh, Vera, Renaud Whittom, P. Desjardins, et al.. (2004). Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial. Lung Cancer. 46(1). 113–118. 7 indexed citations
20.
Samson, Benoît, et al.. (1986). Reply. Canadian Journal of Anesthesia/Journal canadien d anesthésie. 33(6). 829–829. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nadine M Magoski Breakdown of academic impact, for papers by Pranshu Bansal Breakdown of academic impact, for papers by Luis López‐Gómez Breakdown of academic impact, for papers by Anna Tomiak Breakdown of academic impact, for papers by Takanori Kawabata Breakdown of academic impact, for papers by Louise Nott Breakdown of academic impact, for papers by Karen Daily Breakdown of academic impact, for papers by Babar Bashir Breakdown of academic impact, for papers by Jun Dong Breakdown of academic impact, for papers by Dongbok Shin
Rankless by CCL
2026